Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.56 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672097 | 0.98 | CA1 (0.58) | CA1CA2CA12CA9ALOX15 | |
| Bicarbonate SCHEMBL4899567 | 0.94 | CA1 (0.55) | CA1CA2CA12CA9ALOX15 | |
| Butanedione SCHEMBL17913120 | 0.93 | CA1 (0.53) | CA1CA2CA12CA9ALOX15 | |
| Sulfuric Acid SCHEMBL2396292 | 0.91 | CA1 (0.51) | CA1CA2CA12CA9ALOX15 | |
| Pyruvate SCHEMBL4586594 | 0.90 | CA1 (0.50) | CA1CA2CA12CA9ALOX15 | |
| SCHEMBL19152428 | 0.86 | CA1 (0.42) | CA1CA2CA12CA9ALOX15 | |
| SCHEMBL4098848 | 0.83 | CA1 (0.42) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL4586999 | 0.82 | CA12 (0.62) | CA1CA2CA12CA9ALOX15 | |
| Malic Acid SCHEMBL31238937 | 0.82 | CA12 (0.43) | CA1CA2CA12CA9ALOX15 | |
| SCHEMBL4589521 | 0.80 | NAAA (0.43) | CA1CA2CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017886-A1 | FORMULATIONS AND METHODS FOR INCREASING CREATININE LEVELS IN PLASMA, EXTRACELLULAR FLUID AND/OR INTRACELLULAR COMPARTMENTS | VIREO SYSTEMS, INC. (US) | 2025-01-16 | — | — | US | claimed |
| US-20250017904-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF ACTIVATED CREATININE AND AN IMIDAZOLE ANTIFUNGAL AGENT | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2025-01-16 | — | — | US | claimed |
| CN-116606225-A | Preparation method of creatine ethyl ester hydrochloride | 天津天鼎仁科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-116143663-A | Preparation method of creatine ethyl ester hydrochloride | 安徽泰格生物科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-108929249-B | Synthetic process of ethyl creatine hydrochloride | 山东第一医科大学(山东省医学科学院) | 2021-10-08 | — | — | CN | claimed |
| US-20160296449-A1 | Semi-Permanent Hair Straightening Composition And Method | LUBRIZOL ADVANCED MATERIALS, INC. | 2016-10-13 | — | — | US | claimed |
| EP-3065831-A1 | SEMI-PERMANENT HAIR STRAIGHTENING COMPOSITION AND METHOD | Lubrizol Advanced Materials, Inc. (US) | 2016-09-14 | — | — | EP | claimed |
| CN-105916556-A | Semi-permanent hair straightening composition and method | 路博润先进材料公司 | 2016-08-31 | — | — | CN | claimed |
| WO-2015069823-A1 | SEMI-PERMANENT HAIR STRAIGHTENING COMPOSITION AND METHOD | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2015-05-14 | — | — | WO | claimed |
| US-20110172306-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2011-07-14 | — | — | US | claimed |
| US-7786073-B2 | Container for dietary supplement having improved efficacy at time of consumption | HSBC BANK CANADA (CA) | 2010-08-31 | — | — | US | claimed |
| US-20070280996-A1 | Dietary supplement having improved efficacy at time of consumption | HSBC BANK CANADA (CA) | 2007-12-06 | — | — | US | claimed |
| US-20070203076-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2007-08-30 | — | — | US | claimed |
| US-20060251727-A1 | Supplemental dietary composition for increasing muscle size, strength, athletic performance and/or exercise capacity | NEW CELL FORMULATIONS LTD. (CA) | 2006-11-09 | — | — | US | claimed |
| US-12564567-B2 | Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus | VIREO SYSTEMS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250082597-A1 | METHOD FOR TREATING TAUOPATHY IN THE BRAIN, BRAIN STEM AND SPINAL COLUMN | TEDONE 3G LLC (US) | 2025-03-13 | — | — | US | disclosed |
| CN-119462434-A | Preparation method of creatine ethyl ester hydrochloride | 连云港盛和生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20030212130-A1 | Creatine ester anti-inflammatory compounds and formulations | NEBRASKA, UNIVERSITY OF MEDICAL CENTER | 2003-11-13 | — | — | US | disclosed |
| EP-1324760-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | Board of Regents of the University of Nebraska (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002022135-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212130-A1 | Creatine ester anti-inflammatory compounds and formulations | CKMT1A; CKMT1B, CPT1B, CRAT | CA2 901/4885GAA 1972/4885CA1 2415/4885 |
| US-20250017886-A1 | FORMULATIONS AND METHODS FOR INCREASING CREATININE LEVELS IN PLASMA, EXTRACELLULAR FLUID AND/OR INTRACELLULAR COMPARTMENTS | GLS, ALB, REN | CA2 2553/4885GAA 1208/4885CA1 2637/4885 |
| US-20060251727-A1 | Supplemental dietary composition for increasing muscle size, strength, athletic performance and/or exercise capacity | CKMT1A; CKMT1B, CPT1B, GYS1 | CA2 1140/4885GAA 700/4885CA1 2304/4885 |
| US-20250017904-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF ACTIVATED CREATININE AND AN IMIDAZOLE ANTIFUNGAL AGENT | CAT, PRKDC, REN | CA2 521/4885GAA 565/4885CA1 1640/4885 |
| US-12564567-B2 | Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus | CKMT1A; CKMT1B, CPT1B, MAVS | CA2 1074/4885GAA 2004/4885CA1 2568/4885 |
| US-20110172306-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, PYGM | CA2 3569/4885GAA 1272/4885CA1 3741/4885 |
| US-20250082597-A1 | METHOD FOR TREATING TAUOPATHY IN THE BRAIN, BRAIN STEM AND SPINAL COLUMN | BCKDK, ATXN10, SLC1A2 | CA2 1009/4885GAA 4/4885CA1 719/4885 |
| US-20160296449-A1 | Semi-Permanent Hair Straightening Composition And Method | KRT18, PRKDC, DNMT1 | CA2 3006/4885GAA 2921/4885CA1 1157/4885 |
| US-20070203076-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, PYGM | CA2 3569/4885GAA 1272/4885CA1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.